<SEC-DOCUMENT>0001104659-25-003781.txt : 20250115
<SEC-HEADER>0001104659-25-003781.hdr.sgml : 20250115
<ACCEPTANCE-DATETIME>20250115162717
ACCESSION NUMBER:		0001104659-25-003781
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250115

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Poseida Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001661460
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472846548
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91606
		FILM NUMBER:		25533219

	BUSINESS ADDRESS:	
		STREET 1:		9390 TOWNE CENTRE DRIVE
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-779-3100

	MAIL ADDRESS:	
		STREET 1:		9390 TOWNE CENTRE DRIVE
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Malin Life Sciences Holdings Ltd
		CENTRAL INDEX KEY:			0001685138
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		2 HARBOUR SQUARE
		STREET 2:		CROFTON ROAD
		CITY:			DUN LAOGHAIRE, CO, DUBLIN
		STATE:			L2
		ZIP:			----
		BUSINESS PHONE:		353 1 901 5701

	MAIL ADDRESS:	
		STREET 1:		2 HARBOUR SQUARE
		STREET 2:		CROFTON ROAD
		CITY:			DUN LAOGHAIRE, CO, DUBLIN
		STATE:			L2
		ZIP:			----
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-21-011207</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Malin Life Sciences Holdings Ltd -->
          <cik>0001685138</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>01/08/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001661460</issuerCik>
        <issuerName>Poseida Therapeutics, Inc.</issuerName>
        <issuerCusip>73730P108</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>9390 Towne Centre Drive</com:street1>
          <com:street2>Suite 200</com:street2>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Malin Life Sciences Holdings Limited</reportingPersonName>
      <citizenshipOrOrganization>L2</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>0</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Malin Corporation plc</reportingPersonName>
      <citizenshipOrOrganization>L2</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>0</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Poseida Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>9390 Towne Centre Drive, Suite 200, San Diego, California 92121</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Malin Life Sciences Holdings Limited; Malin Corporation plc</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The Lennox Building, 50 Richmond Street South, Dublin, Ireland L2 D02 FK02</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Ireland</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See the responses to Items 5-9 on the attached cover pages.</amountBeneficiallyOwned>
        <classPercent>See the responses to Item 11 on the attached cover pages.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See the responses to Item 6 on the attached cover pages.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See the responses to Item 8 on the attached cover pages.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Malin Life Sciences Holdings Limited</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Fiona Dunlevy</signature>
        <title>Fiona Dunlevy, Company Secretary</title>
        <date>01/15/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Malin Corporation plc</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Fiona Dunlevy</signature>
        <title>Fiona Dunlevy, Company Secretary</title>
        <date>01/15/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
